Lenalidomide for the Treatment of Resistant Discoid Lupus Erythematosus | Zendy

Asha Shah | Zendy; Joerg Albrecht | Zendy; Zuleika L. Bonilla-Martinez | Zendy; Joyce Okawa | Zendy; Mathew Rose | Zendy; Misha Rosenbach | Zendy; Victoria P. Werth | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Lenalidomide for the Treatment of Resistant Discoid Lupus Erythematosus

Author(s) -

Asha Shah,

Joerg Albrecht,

Zuleika L. Bonilla-Martinez,

Joyce Okawa,

Mathew Rose,

Misha Rosenbach,

Victoria P. Werth

Publication year - 2009

Publication title -

archives of dermatology

Language(s) - English

Resource type - Journals

eISSN - 1538-3652

pISSN - 0003-987X

DOI - 10.1001/archdermatol.2009.30

Subject(s) - medicine , lenalidomide , discoid lupus erythematosus , dermatology , lupus erythematosus , systemic lupus erythematosus , immunology , antibody , disease , multiple myeloma

Discoid lupus erythematosus (DLE) is a chronic, disfiguring disease that is characterized by scaly, erythematous, disk-shaped patches and plaques followed by atrophy, scarring, and dyspigmentation. It is refractory to standard therapies in a small population of patients. We investigated the use of lenalidomide, a thalidomide analogue, as a novel alternative therapy in 2 cases of refractory DLE and report our results.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research